LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

Kodu・Aktsiate loetelu・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Suletud

8.3 1.34

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.91

Max

8.51

Põhinäitajad
By Trading Economics
Sissetulek	4.2M -23M
Kasumimarginaal	-2,027.003
Töötajad	83
EBITDA	6.6M -23M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+67.4% upside

Turustatistika
By TradingEconomics
Turukapital	41M 628M
Eelmine avamishind	6.96
Eelmine sulgemishind	8.3

Ventyx Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. dets 2025, 17:39 UTC

Suurimad hinnamuutused turgudel

Vanda Pharmaceuticals Rises on FDA Biologics License Application

15. dets 2025, 23:44 UTC

Market Talk

Gold Steady Ahead of U.S. Employment Report -- Market Talk

15. dets 2025, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

15. dets 2025, 23:38 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

15. dets 2025, 22:19 UTC

Market Talk

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

15. dets 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

15. dets 2025, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

15. dets 2025, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

15. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

15. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

15. dets 2025, 21:23 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

15. dets 2025, 21:23 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

15. dets 2025, 21:23 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

15. dets 2025, 21:22 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

15. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

15. dets 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Completes Acquisition Of Moveworks >NOW

15. dets 2025, 21:00 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15. dets 2025, 20:57 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15. dets 2025, 20:36 UTC

Market Talk

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

15. dets 2025, 20:31 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

15. dets 2025, 20:27 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

15. dets 2025, 20:15 UTC

Market Talk

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

15. dets 2025, 19:22 UTC

Market Talk

Gold and Silver Gain to Start Week -- Market Talk

15. dets 2025, 18:37 UTC

Market Talk

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

15. dets 2025, 18:29 UTC

Market Talk

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

15. dets 2025, 17:58 UTC

Market Talk

Canada Housing Market In Search Of a Bottom -- Market Talk

15. dets 2025, 17:36 UTC

Market Talk

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

15. dets 2025, 17:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. dets 2025, 17:36 UTC

Tulu

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

15. dets 2025, 17:30 UTC

Omandamised, ülevõtmised, äriostud

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Ventyx Biosciences Inc Prognoos

Hinnasiht

By TipRanks

67.4% tõus

12 kuu keskmine prognoos

Keskmine 13.71 USD 67.4%

Kõrge 21 USD

Madal 2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ventyx Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Ventyx Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.